218 related articles for article (PubMed ID: 26439622)
1. Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Tsutsumi Y; Nomiyama T; Kawanami T; Hamaguchi Y; Terawaki Y; Tanaka T; Murase K; Motonaga R; Tanabe M; Yanase T
PLoS One; 2015; 10(10):e0139709. PubMed ID: 26439622
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
Nomiyama T; Kawanami T; Irie S; Hamaguchi Y; Terawaki Y; Murase K; Tsutsumi Y; Nagaishi R; Tanabe M; Morinaga H; Tanaka T; Mizoguchi M; Nabeshima K; Tanaka M; Yanase T
Diabetes; 2014 Nov; 63(11):3891-905. PubMed ID: 24879833
[TBL] [Abstract][Full Text] [Related]
3. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
4. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
5. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F
Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742
[TBL] [Abstract][Full Text] [Related]
6. Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.
Iwaya C; Nomiyama T; Komatsu S; Kawanami T; Tsutsumi Y; Hamaguchi Y; Horikawa T; Yoshinaga Y; Yamashita S; Tanaka T; Terawaki Y; Tanabe M; Nabeshima K; Iwasaki A; Yanase T
Endocrinology; 2017 Dec; 158(12):4218-4232. PubMed ID: 29045658
[TBL] [Abstract][Full Text] [Related]
7. Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model.
Chen BD; Zhao WC; Jia QA; Zhou WY; Bu Y; Wang ZZ; Wang F; Wu WJ; Wang Q
Int J Mol Sci; 2013 Dec; 14(12):24293-304. PubMed ID: 24351817
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
Li XN; Bu HM; Ma XH; Lu S; Zhao S; Cui YL; Sun J
Exp Clin Endocrinol Diabetes; 2017 Feb; 125(2):91-97. PubMed ID: 28008585
[No Abstract] [Full Text] [Related]
9. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.
Zhang Y; Xu F; Liang H; Cai M; Wen X; Li X; Weng J
Oncol Rep; 2016 Mar; 35(3):1340-8. PubMed ID: 26648451
[TBL] [Abstract][Full Text] [Related]
10. Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Shigeoka T; Nomiyama T; Kawanami T; Hamaguchi Y; Horikawa T; Tanaka T; Irie S; Motonaga R; Hamanoue N; Tanabe M; Nabeshima K; Tanaka M; Yanase T; Kawanami D
J Diabetes Investig; 2020 Sep; 11(5):1137-1149. PubMed ID: 32146725
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis.
Fan R; Li X; Gu X; Chan JC; Xu G
Diabetes Obes Metab; 2010 Sep; 12(9):815-24. PubMed ID: 20649634
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth.
Tanaka Y; Iwaya C; Kawanami T; Hamaguchi Y; Horikawa T; Shigeoka T; Yanase T; Kawanami D; Nomiyama T
Diabetol Int; 2022 Jul; 13(3):480-492. PubMed ID: 35693999
[TBL] [Abstract][Full Text] [Related]
13. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Colquhoun AJ; Venier NA; Vandersluis AD; Besla R; Sugar LM; Kiss A; Fleshner NE; Pollak M; Klotz LH; Venkateswaran V
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):346-52. PubMed ID: 22614062
[TBL] [Abstract][Full Text] [Related]
14. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
O'Brien AJ; Villani LA; Broadfield LA; Houde VP; Galic S; Blandino G; Kemp BE; Tsakiridis T; Muti P; Steinberg GR
Biochem J; 2015 Jul; 469(2):177-87. PubMed ID: 25940306
[TBL] [Abstract][Full Text] [Related]
15. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
16. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.
Wang ZS; Huang HR; Zhang LY; Kim S; He Y; Li DL; Farischon C; Zhang K; Zheng X; Du ZY; Goodin S
Biol Pharm Bull; 2017; 40(8):1247-1254. PubMed ID: 28769006
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells.
Fidan-Yaylalı G; Dodurga Y; Seçme M; Elmas L
Tumour Biol; 2016 Feb; 37(2):2647-53. PubMed ID: 26399993
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
20. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
